Biotech

EU regulation proves its worth in driving innovation

It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton
06 Feb 2013